Endocyte (ECYT +6.1%) ramps higher after Baird upgrades the stock to Outperform with a $13 price...

|By:, SA News Editor

Endocyte (ECYT +6.1%) ramps higher after Baird upgrades the stock to Outperform with a $13 price target and says the company's chemo drug Vintafolide should be a "catalyst" going forward.